Differentiation-inducing factor-1 suppresses the expression of c-Myc in the human cancer cell lines

Kentaro Jingushi1, Toshihisa Nakamura, Fumi Takahashi-Yanaga

  • 1Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

Insights

Differentiation-inducing factor-1 (DIF-1) inhibits cancer cell growth by reducing c-Myc protein and mRNA. This novel anti-cancer agent targets the Wnt/β-catenin pathway via GSK-3β activation.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Differentiation-inducing factor-1 (DIF-1) is a morphogen that inhibits cancer cell proliferation.
  • The Wnt/β-catenin signaling pathway is crucial in cancer development and progression.
  • c-Myc is a key oncogene and a downstream target of the Wnt/β-catenin pathway.

Purpose of the Study:

  • To investigate the effect of DIF-1 on c-Myc expression in human cancer cells.
  • To elucidate the mechanism by which DIF-1 affects c-Myc.
  • To determine if c-Myc is involved in the anti-proliferative effects of DIF-1.

Main Methods:

  • Utilized HCT-116 colon and HeLa cervical cancer cell lines.
  • Assessed c-Myc protein and mRNA levels following DIF-1 treatment.
  • Investigated promoter activity and employed proteasome and GSK-3β inhibitors.
  • Examined the role of c-Myc using c-Myc-overexpressing cells.

Main Results:

  • DIF-1 significantly reduced c-Myc protein and mRNA levels in a dose- and time-dependent manner.
  • DIF-1 inhibited c-Myc promoter activity via TCF binding sites.
  • DIF-1-induced c-Myc degradation involved GSK-3β activation.
  • c-Myc was confirmed to be associated with the anti-proliferative effect of DIF-1.

Conclusions:

  • DIF-1 suppresses c-Myc expression by inhibiting promoter activity and promoting protein degradation via GSK-3β.
  • DIF-1's anti-proliferative action is mediated, in part, by its effect on c-Myc.
  • DIF-1 shows potential as a novel anti-cancer therapeutic agent targeting c-Myc.

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...